Medicare covers the injectable drug, Reclast, when a doctor deems it medically necessary for the treatment and prevention of osteoporosis. There are specific eligibility criteria, including having ...

Reclast (zoledronic acid) is a medication that the Food and Drug Administration (FDA) has approved for preventing and treating osteoporosis in females after menopause, males, and individuals who take ...

EAST HANOVER, N.J., Oct. 16 Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast® (zoledronic acid) injection in postmenopausal ...

Research published in the New England Journal of Medicine gives that an annual infusion of Novartis AG's Reclast after a mild hip fracture not only helps prevent another broken bone, it prolongs life ...

Zoledronic acid 5 mg/100 mL bottle; solution for IV infusion. Paget’s disease of bone is characterized by greatly increased and disorderly bone remodeling. Excessive osteoclastic bone resorption is ...

The U.S. Food and Drug Administration (FDA) has approved Reclast® (zoledronic acid) Injection, the first and only once-yearly treatment for postmenopausal osteoporosis. Approximately 8 million women ...

The FDA has approved Reclast (zoledronic acid, from Novartis) injection for the prevention of osteoporosis in women for two years with a single dose. This approval was based on a study involving more ...

A new drug called Reclast may make it possible to reduce osteoporosis fractures with a single annual infusion that takes 15 minutes. Reclast's maker, Novartis, is preparing to submit Reclast for FDA ...

The FDA has approved Reclast (zoledronic acid injection, from Novartis) for the prevention of new clinical fractures in patients who have recently had a low-trauma hip fracture. The approval was based ...

Reclast (zoledronic acid or zoledronate) is approved by the Food and Drug Administration (FDA) to treat and prevent osteoporosis in males, females after menopause, and people taking glucocorticoids.